United Therapeutics Co. (UTHR) Position Lessened by Colony Group LLC

Colony Group LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 89.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,804 shares of the biotechnology company’s stock after selling 40,822 shares during the quarter. Colony Group LLC’s holdings in United Therapeutics were worth $544,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Legacy Financial Advisors Inc. acquired a new position in shares of United Therapeutics during the second quarter worth about $107,000. Sun Life Financial INC acquired a new position in shares of United Therapeutics during the second quarter worth about $198,000. Trexquant Investment LP acquired a new position in shares of United Therapeutics during the first quarter worth about $266,000. Fox Run Management L.L.C. acquired a new position in shares of United Therapeutics during the second quarter worth about $269,000. Finally, Opus Point Partners Management LLC increased its stake in shares of United Therapeutics by 25.8% during the first quarter. Opus Point Partners Management LLC now owns 2,579 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 529 shares during the period. Institutional investors and hedge funds own 95.83% of the company’s stock.

In other United Therapeutics news, Director Richard Giltner sold 3,240 shares of the company’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 810 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the completion of the sale, the director now directly owns 3,925 shares in the company, valued at approximately $463,150. The disclosure for this sale can be found here. Insiders sold 4,860 shares of company stock worth $611,161 in the last ninety days. Insiders own 8.20% of the company’s stock.

Several research analysts have weighed in on the stock. HC Wainwright restated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research report on Thursday, August 2nd. Wedbush upped their target price on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research report on Thursday, August 2nd. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Thursday, August 16th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 target price on the stock in a research report on Saturday, July 7th. Finally, BidaskClub lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, September 24th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $138.86.

Shares of UTHR opened at $126.65 on Tuesday. The company has a current ratio of 4.64, a quick ratio of 4.35 and a debt-to-equity ratio of 0.10. United Therapeutics Co. has a twelve month low of $100.57 and a twelve month high of $152.55. The stock has a market cap of $5.57 billion, a price-to-earnings ratio of 11.55, a P/E/G ratio of 28.86 and a beta of 1.20.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The company had revenue of $444.50 million for the quarter, compared to the consensus estimate of $368.63 million. During the same quarter in the prior year, the firm earned $4.37 earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Co. will post 14.77 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading: What are earnings reports?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply